Pfizer has advanced its obesity strategy by reporting positive mid-stage clinical results for a long-acting version of the oral peptide danuglipron. Acquired through the purchase of biotech firm Metsera, the therapy is being developed as a once-monthly injection to help patients maintain weight loss. Despite the clinical milestone, investor sentiment cooled as the market awaits detailed comparisons to current market leaders.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.